May 14, 2014 — Data presented during Heart Rhythm 2014 found the use of quadripolar leads reduced the number of hospitalizations by 53 percent when compared to the non-quadripolar group. This hospitalization rate reduction translated into a statistically significant 62 percent reduction in overall costs for both healthcare systems and patients.

May 14, 2014 — Vivek Reddy, M.D., director of arrhythmia services for The Mount Sinai Hospital, reported promising 12-month follow-up data showing the world's first leadless pacemaker is demonstrating overall device performance comparable to conventional pacemakers. Reddy presented the one-year LEADLESS study data findings during a late-breaking clinical trial presentation on Heart Rhythm 2014, the Heart Rhythm Society's (HRS) 35th annual scientific sessions in San Francisco.

May 14, 2014 — Detroit Medical Center (DMC) Harper Hospital presented a live CorPath robotic-assisted percutaneous coronary intervention (PCI), or coronary angioplasty, during the American College of Cardiology (ACC) annual meeting this year. The procedure, which was transmitted live to Washington, D.C., for meeting attendees, was led by Ted Schreiber, M.D., president of the Cardiovascular Institute and director of the Cardio One team at DMC Harper Hospital.


May 13, 2014 — The Heart Rhythm Society (HRS), American College of Cardiology (ACC) and American Heart Association (AHA) released Expert Consensus Statement on the Use of Implantable Cardioverter Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials at Heart Rhythm 2014, the 35th annual scientific sessions of HRS. The expert consensus statement provides first-of-its-kind guidance on ICD therapy for the management of patient populations who are not well represented in clinical trials and, as a result, not specifically included in existing guidelines.

Esaote North America received U.S. Food and Drug Administration (FDA) clearance to market and sell its Virtual Navigator fusion imaging technology for ultrasound to U.S. customers.

 
Boston Scientific Corp. ICD HRS 35th Annual Scientific Sessions SIMPLE Trial

A Boston Scientific Corp. study demonstrated that outcomes for patients with the company's transvenous implantable cardioverter defibrillators (ICD) who received routine defibrillation testing (DT) at implant were similar to outcomes for those patients who did not receive defibrillation testing. 
Elixir Medical Corp. DESolve 100 CE mark

Elixir Medical Corp. received CE mark approval for its DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now